Teva Pharmaceutical Industries, Ltd.
USPTO PatentsView assignee record - 74 granted patents across 17 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Teva ranks #4,741 of 49,997 tracked US assignees by granted-patent volume, with 74 patents across 17 technology areas.
- #4,741
- of 49,997 US assignees by volume
- Top 25%
- by Innovation Score (44.5/100)
- 13.8
- avg claims per patent
- -93%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R4741 · Foreign Corporation #4,741 · 74 grants
GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 74 grants
- TOP-DECILE #4,741/49,997
- PHOTO-FINISH Solystic
- CPC-FOCUS A61P · 17 areas
- INNOV-PAR 44.5/100
- CLAIMS-RICH 13.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -93% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Solystic (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Teva’s 44.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Teva
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Diveplane · near
Diveplane · near
44 score
- Doskocil Manufacturing · near
Doskocil Manufacturing · near
44 score
- Santa Clara University · near
Santa Clara University · near
44 score
- Santen Pharmaceutical · near
Santen Pharmaceutical · near
44 score
- Teva Pharmaceutical… · this assignee
Teva Pharmaceutical… · this assignee
44 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Teva's Innovation Score is 44.5/100 (top 25% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Teva?
Each dot is one of Teva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Teva’s own 13.8 claims/patent is ABOVE the 11.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Teva's grants concentrate
Teva Pharmaceutical Industries, Ltd. is a focused PatentsView assignee: 17 CPC subclasses with 45.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (34 grants) versus a trough of 1 in 2019. By volume, Teva sits between Solystic and Victor Equipment Company.
Teva's three-year grant acceleration
Teva Pharmaceutical Industries, Ltd. shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Teva's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Solystic
Solystic
74 patents
- Sotera Wireless
Sotera Wireless, Inc.
74 patents
- Taiyo Nippon Sanso
Taiyo Nippon Sanso Corporation
74 patents
- TDK—Micronas
TDK—Micronas GmbH
74 patents
- Teijin Pharma
Teijin Pharma Limited
74 patents
- Tokyo Seimitsu
Tokyo Seimitsu Co., Ltd.
74 patents
- Universite Paris-…
Universite Paris-saclay
74 patents
- Victor Equipment
Victor Equipment Company
74 patents
- Teva Pharmaceutic… ◀
Teva Pharmaceutical Industries, Ltd.
74 patents
What this shows Teva holds 74 patents at rank #4,740, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Teva
By rank, the assignees closest to #4,740 in granted patent volume.
- Solystic #4,736 · 74 patents
- Sotera Wireless, Inc. #4,737 · 74 patents
- Taiyo Nippon Sanso Corporation #4,738 · 74 patents
- TDK—Micronas GmbH #4,739 · 74 patents
- Teijin Pharma Limited #4,741 · 74 patents
- Tokyo Seimitsu Co., Ltd. #4,742 · 74 patents
- Universite Paris-saclay #4,743 · 74 patents
- Victor Equipment Company #4,744 · 74 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Teva's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Teva, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Teva ranks #560 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (44 here).
Similar claim depth
Nearest assignees by average claims per patent (13.8 here).
Teva's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
44 Top 25% higher than 75% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 19 | 25.7% |
| 2016 | 10 | 13.5% |
| 2017 | 34 | 45.9% |
| 2018 | 4 | 5.4% |
| 2019 | 1 | 1.4% |
| 2021 | 2 | 2.7% |
| 2022 | 1 | 1.4% |
| 2023 | 1 | 1.4% |
| 2024 | 1 | 1.4% |
| 2025partial year | 1 | 1.4% |
Which technologies does Teva Pharmaceutical Industries, Ltd. patent most?
Top 15 of 17 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Teva Pharmaceutical Industries, Ltd.'s patent record in context - here's where to go next.
- Teva Pharmaceutical Industries, Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 45.9% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #4,741 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Teva Pharmaceutical Industries, Ltd. against Solystic, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 44.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.